Work

Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study

Year: 2024

Type: article

Abstract: Triple-negative breast cancer (TNBC) is an aggressive heterogeneous form of breast cancer that accounts for 15 %-20 % of all breast cancers. Characterized by an absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, TNBCs are often treated with surgery, chemotherapy, radiation, and, most recently, with immunotherapy; however, patients with treatment-resistant TNBC often relapse and have an extremely poor prognosis. Here we present a case of recurrent metastatic TNBC responsive to the TRK inhibitor larotrectinib.

Source: Current Problems in Cancer Case Reports

DOI: 10.1016/j.cpccr.2024.100334

Authors: Martin Dietrich, Michel Velez

Institutions: University of Central Florida, Holy Cross Hospital

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $830